Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares


NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a business stage biotechnology firm targeted on revolutionary aesthetic and therapeutic choices (“Revance” or the “Firm”), right now introduced the closing of its beforehand introduced underwritten public providing of 9,200,000 shares of its widespread inventory, which incorporates the complete train of the underwriters’ choice to buy 1,200,000 further shares, at a worth to the general public of $25.00 per share. All the shares had been provided by Revance. The combination gross proceeds from the general public providing had been $230.0 million, earlier than deducting underwriting reductions and commissions and different providing bills.

Goldman Sachs & Co. LLC, Cowen and Firm, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the providing. Barclays Capital Inc. additionally acted as a bookrunner for the providing.

The securities described above had been provided by Revance pursuant to an computerized shelf registration assertion on Kind S-3 (File No. 333-250998) beforehand filed with the Securities and Alternate Fee (the “SEC”) on November 27, 2020. A remaining prospectus complement and accompanying prospectus referring to the general public providing had been filed with the SEC and can be found on the SEC’s web site at Copies of the ultimate prospectus complement and accompanying prospectus may additionally be obtained by contacting Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Road, New York, NY 10282, by phone at 1-866-471-2526, or by e-mail at [email protected]; Cowen and Firm, LLC, c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, NY 11717, Attn: Prospectus Division, by phone at (833) 297-2926, or by e-mail at [email protected]; Guggenheim Securities, LLC, Consideration: Fairness Syndicate Division, 330 Madison Avenue, eighth Flooring, New York, New York 10017, or by phone at (212) 518-9544, or by e-mail at [email protected]; or Barclays Capital Inc., c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, New York 11717, by phone at (888) 603-5847, or by e-mail at [email protected].

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or different jurisdiction during which such supply, solicitation or sale can be illegal previous to the registration or qualification underneath the securities legal guidelines of any such state or different jurisdiction.

About Revance

Revance is a business stage biotechnology firm targeted on creating and commercializing revolutionary aesthetic and therapeutic choices, together with DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection, the RHA® Assortment of dermal fillers, and OPUL®, a relational commerce platform for aesthetic practices. Revance has additionally partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which might compete within the present short-acting neuromodulator market. Revance’s therapeutics pipeline is at the moment targeted on muscle motion issues together with evaluating DaxibotulinumtoxinA for Injection in cervical dystonia and higher limb spasticity.

Revance, the Revance brand and OPUL® are registered logos of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are registered logos of Teoxane SA.

BOTOX® is a registered trademark of Allergan, Inc.